Farmakoekonomika

Aims & Scope

The main goal of the journal is to publish high-quality original articles, scientific reviews, and the best practical examples in the area of health economics and outcomes research (HEOR) as well as pharmacoepidemiology.

Our priorities focus on scientific and information support to the decision-makers and experts in public drug supply, health providers, research and education professionals, as well as pharmaceutic and insurance companies.

Among the peer-reviewed journals in this field, this journal is considered the first and most reputable in Russia and the EurAsEC (Eurasian Economic Community) countries.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Embase

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine and Pharmacology, Toxicology and Pharmaceutics, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 15,000.00 RUB. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard

  Citation: 47

  Authors: I. Yu., A. M., A. V., A. Yu., L. I., E. A., I. V., A. N., A. N., A. K., L. V., E. F., M. I., O. A.

• Strengthening health care to provide rehabilitation services for women with cancer diseases of the reproductive system

  Citation: 27

  Authors: D. V., A. G., A. N., D. M., L. N., D. I., D. A.

• Analysis of 19.9 million publications from the PubMed/MEDLINE database using artificial intelligence methods: approaches to the generalizations of accumulated data and the phenomenon of “fake news

  Citation: 23

  Authors: I. Yu., O. A., L. V., N. P., A. N., Zh. D., T. R., A. N., I. A., V. M., A. G., O. A., V. A., S. I., E. V., N. I., K. V., V. A.

• COVID-19 in Moscow: prognoses and scenarios

  Citation: 19

  Authors: M. V.

• Pharmacoepidemiology and pharmacoeconomics of multidrug- and extensively drug-resistant tuberculosis

  Citation: 18

  Authors: N. Yu., D. А., N. P.

• New framework for the development of clinical guidelines in Russia

  Citation: 17

  Authors: D. V., E. S., A. S., E. V., D. I.

• Differences in the standardization of medicinal products based on extracts of chondroitin sulfate

  Citation: 16

  Authors: O. A., I. Yu., B. Ts., E. V., A. O., A. N., I. S., I. V.

• Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system

  Citation: 14

  Authors: T. S., N. Z., V. V.

• Concerning the “repression” of ω -3 polyunsaturated fatty acids by adepts of evidence-based medicine

  Citation: 14

  Authors: I. Yu., O. A., Zh. D.

• SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION

  Citation: 14

  Authors: A.E., N.A., M.V., E.V., O.V., A.V., N.M.